pyrroles has been researched along with Adenocarcinoma in 99 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.03) | 18.7374 |
| 1990's | 4 (4.04) | 18.2507 |
| 2000's | 18 (18.18) | 29.6817 |
| 2010's | 65 (65.66) | 24.3611 |
| 2020's | 9 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, E; Kim, SS; Ryu, MO | 1 |
| Fernandes, AFA; Heaton, CM; Jark, PC; Pan, X | 1 |
| Akiyoshi, H; Mie, K; Miura, N; Nishida, H; Tanaka, T; Yamazaki, H | 1 |
| Chen, Y; Feng, D; Jiang, R; Li, G; Liu, S; Peng, R; Wei, L; Zheng, S | 1 |
| Abe, Y; Asano, N; Fujishima, F; Hatta, W; Imatani, A; Jin, X; Kanno, T; Koike, T; Masamune, A; Nakagawa, K; Saito, M; Uno, K | 1 |
| Graham, DY; Howden, CW | 1 |
| Chen, CT; Deshpande, V; Goyal, L; Pierce, TT | 1 |
| Johannes, CM; Musser, ML | 1 |
| Li, J; Xu, H | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Jia, W; Liu, Y; Min, L; Qiankun, Z; Sun, W; Wang, WH; Wu, D; Yang, H; Yang, Y; Zhang, H; Zhang, J; Zhang, Y | 1 |
| Cao, Y; Gu, L; Liao, S; Ma, Q; Wang, Y; Zhang, J; Zhang, S; Zheng, Y | 1 |
| Elliott, JW | 1 |
| Iguchi, A; Kobayashi, S; Mitsui, I; Ooshida, J; Satou, R; Uchida, N; Yamasaki, M | 1 |
| Mankal, P; O'Reilly, E | 1 |
| Corn, PG; DePetrillo, TA; Heath, E; Kuban, D; Maier, J; Mathew, P; Meyn, R; Song, DY | 1 |
| Chang, TT; Chiao, YP; Jao, SC; Li, WS; Lu, CK; More, SV | 1 |
| Bahleda, R; Escudier, B; Gueutin, V; Izzedine, H; Rouvier, P; Soria, JC; Varga, A | 1 |
| Campiani, G; Greene, LM; Nolan, DP; Regan-Komito, D; Williams, DC; Zisterer, DM | 1 |
| Saif, MW; Sarris, EG; Syrigos, KN | 1 |
| Gruidl, M; Timme, CR; Yeatman, TJ | 1 |
| Aprile, G; Belli, C; Bergamo, F; Ceraulo, D; Cereda, S; Danova, M; Di Lucca, G; Franceschi, E; Fugazza, C; Mambrini, A; Milella, M; Novarino, A; Passardi, A; Reni, M; Villa, E | 1 |
| Bang, YJ; Khosravan, R; Lechuga, MJ; Lee, KW; Lee, SY; Lin, X; Oh, DY; Park, SR; Park, YI; Roh, EJ; Valota, O | 1 |
| Asanuma, K; Cheng, E; Genta, RM; Hatanpaa, KJ; Huo, X; Melton, S; Peng, S; Pham, TH; Rezai, D; Sarode, V; Souza, RF; Spechler, SJ; Wang, DH; Wright, E; Xu, H; Yu, C; Zhang, Q; Zhang, X | 1 |
| Gandhi, L; Heist, RS; Hodgson, L; Otterson, GA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X; Watson, P | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Dome, B; Fehniger, TE; Hegedus, B; Laszlo, V; Marko-Varga, G; Paku, S; Rezeli, M; Rozsas, A; Torok, S; Tovari, J; Vegvari, A | 1 |
| Aulitzky, WE; Bergmann, L; Burkholder, I; Edler, L; Fuxius, S; Hartung, G; Heil, G; Köberle, D; Maute, L; Moritz, B; Richly, H; Rüssel, J; Scheulen, ME; Weidmann, E; Weigang-Köhler, K; Wörmann, B | 1 |
| Cagnon, VH; Hetzl, AC; Kido, LA; Montico, F | 1 |
| Bonzi, MC; Craparotta, I; Gariboldi, MB; Giovannardi, S; Mancini, M; Monti, E; Taiana, E | 1 |
| Hainsworth, JD; Midha, R; Peacock, NW; Priego, VM; Shastry, M; Shipley, DL; Yardley, DA | 1 |
| Shih, JY; Wu, H; Yang, JC | 1 |
| Abe, H; Hirano, S; Hiraoka, K; Hontani, K; Inoko, K; Kushibiki, T; Nakamura, T; Nishihara, H; Sato, N; Sato, S; Shichinohe, T; Takahashi, M; Takano, H; Takeuchi, S; Tsuchikawa, T | 1 |
| Huggett, MT; Keane, MG; Loddo, M; Pereira, SP; Proctor, I; Stoeber, K; Tudzarova, S; Williams, GH | 1 |
| Brekken, RA; Goel, HL; Greiner, DL; Mercurio, AM; Pursell, B; Shultz, LD; Vander Kooi, CW | 1 |
| Chen, G; Li, YH; Wang, DC; Wang, LC; Wang, LJ; Zhao, YX; Zhao, ZF | 1 |
| Jeong, YK; Jung, WG; Kim, EH; Lee, H | 1 |
| Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Chakravarthy, AB; Cuneo, KC; Fu, A; Geng, L; Hallahan, DE; Orton, D | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Asmar, L; Berry, WR; Boehm, KA; Hutson, TE; Sonpavde, G | 1 |
| Dror Michaelson, M; Gurski, C; Kantoff, PW; Kaufman, DS; Michaelson, SZ; Oh, WK; Olivier, K; Regan, MM; Smith, MR; Spicer, B | 1 |
| Adachi, Y; Arimura, Y; Carbone, DP; Imai, K; Imsumran, A; Lee, CT; Li, H; Li, R; Min, Y; Piao, W; Shinomura, Y; Wang, Y; Yamamoto, H | 1 |
| Battistella, M; Boukoucha, M; Chami, L; Cribier, B; Duvillard, P; Lassau, N; Mateus, C; Robert, C | 1 |
| Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L | 1 |
| Baritaki, S; Berenson, J; Bonavida, B; Palladino, M; Yeung, K | 1 |
| Cho, YJ; Datta, A; Datta, PK; Gorden, DL; Halder, SK; Kashikar, ND; Zhang, B | 1 |
| Kolb, MM; Kozloff, MF; Samant, M; Scappaticci, FA; Socinski, MA | 1 |
| Blesa, JM; Pulido, EG | 1 |
| Bang, YJ; Boku, N; Chen, JS; Chung, HC; Doi, T; Kang, WK; Kang, YK; Lechuga, MJ; Lu, DR; Ng, WT; Qin, S; Ruiz-Garcia, A; Shen, L; Sobrero, A; Sun, Y; Tursi, JM | 1 |
| Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM | 1 |
| Bories, E; Caillol, F; Giovannini, M; Gravis, G; Jeanniard-Malet, O; Pesenti, C | 1 |
| An, J; Bilenky, M; Birol, I; Butterfield, YS; Cezard, T; Chuah, E; Corbett, R; Fejes, AP; Griffith, M; Griffith, OL; Hirst, M; Holt, RA; Huntsman, DG; Jones, SJ; Laskin, J; Li, YY; Marra, MA; Martin, M; Mayo, M; Melnyk, N; Moore, RA; Morin, RD; Pugh, TJ; Severson, T; Shah, SP; Sutcliffe, M; Tam, A; Terry, J; Thiessen, N; Thomson, T; Varhol, R; Yee, J; Zeng, T; Zhao, Y | 1 |
| Abrantes, AM; Beja, AM; Botelho, MF; Brito, AF; Laranjo, M; Paixão, JA; Pinho E Melo, TM; Silva, MR; Soares, MI | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Campiani, G; Cloonan, SM; Lawler, M; Nathwani, SM; Stronach, M; Williams, DC; Zisterer, DM | 1 |
| Sulkes, A | 1 |
| Abou-Alfa, GK; Bekaii-Saab, T; Douglas, K; Goldberg, RM; Hall, M; Hollis, D; Kindler, HL; Niedzwiecki, D; O'Reilly, EM; Pluard, T; Schilsky, RL | 1 |
| Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G | 1 |
| Abrey, L; Camps, C; Chao, RC; Grossi, F; Mazieres, J; Novello, S; Patyna, S; Scagliotti, G; Thall, A; Usari, T; Vernejoux, JM; Wang, Z | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Cunningham, D; Okines, AF; Reynolds, AR | 1 |
| Antón-Aparicio, LM; Cassinello, J; Castellano, D; Esteban, E; González-Larriba, JL; Grande, E; Sepúlveda, J | 1 |
| du Parcq, J; Fisher, C; Larkin, JM; Livni, N; Thway, K | 1 |
| DeCastro, A; Janakiram, NB; Lee, HJ; Paul, S; Rao, CV; Reddy, BS; Simi, B; Smolarek, AK; So, JY; Steele, V; Suh, N; Wang, CX | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE | 1 |
| Gao, H; Guo, W; Liu, X | 1 |
| Avella, DM; Berg, A; Garcia, LS; Isom, HC; Kester, M; Kimchi, ET; Li, G; Liu, D; Lou, X; Rountree, CB; Schell, TD; Shereef, S; Staveley-O'Carroll, KF; Tagaram, HR; Yang, Q; Zhang, SS | 1 |
| Fullerton, DA; Meng, X; Reece, TB; Reppert, AE; Sadaria, MR; Weyant, MJ; Yu, JA | 1 |
| Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H | 1 |
| Doval, DC; Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Thongprasert, S; Yi, JH | 1 |
| Alvarez, F; Beaver, L; Bryan, J; Carreras, J; Clifford, C; Ettinger, S; Fulton, L; Gauthier, M; Gill, V; Gillings, S; Haney, S; Henry, C; Hershey, B; Higginbotham, ML; Hillman, L; Jones, P; Kiselow, M; Klein, MK; Krick, E; Ladue, T; London, C; Mathie, T; McNeill, C; Novasad, A; Phillips, B; Stingle, N; Thamm, D; Vail, DM; Vaughan, A; Vickery, K | 1 |
| Bellail, AC; Ding, L; Hao, C; Liu, Y; Lu, G; Olson, JJ; Sun, SY; Wang, G; Wei, F; Yuan, C | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS | 1 |
| Denda, T; Hashigaki, S; Kato, T; Komatsu, Y; Lechuga, MJ; Miyata, Y; Mizutani, N; Muro, K; Nagase, M; Nishina, T; Satoh, T; Tsuji, A; Tsuji, Y; Yoshida, M | 1 |
| Barck, KH; Cao, TC; Carano, RA; Cheng, JH; Couto, SS; Eastham-Anderson, J; Ferrara, N; Foreman, O; Forrest, WF; Hamilton, P; Ho, CC; Johnson, L; Jubb, AM; Kasman, I; Lima, A; Long, JE; McNutt, A; Molina, R; Nannini, MA; Reslan, HB; Singh, M | 1 |
| Bellmunt, J; Gil-Martín, M; Gómez-Martín, C; Khosravan, R; Lechuga, MJ; Lin, X; Montagut, C; Núñez, JA; Puig, M; Salazar, R; Tursi, JM | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Buchanan, GO; Feling, RH; Fenical, W; Jensen, PR; Kauffman, CA; Mincer, TJ | 1 |
| CAMPBELL, GW; DULANEY, EL; GITTERMAN, CO; HENDLIN, D; KACZKA, EA; WOODRUFF, HB | 1 |
| Fedier, A; Fink, D; Fowst, C; Geroni, C; Haller, U; Marchini, S; Tursi, J | 1 |
| Abdollahi, A; Bischof, M; Debus, J; Grone, HJ; Hahnfeldt, P; Han, X; Hlatky, L; Huber, PE; Klenke, F; Krix, M; Lipson, KE; Poerschke, D; Roth, A; Sckell, A; Zieher, H | 1 |
| Bruns, CJ; Guba, M; Jauch, KW; Kleespies, A | 1 |
| Kohno, T; Konno, R; Machida, S; Mizuno, I; Ohwada, M; Saga, Y; Suzuki, M; Takayama, T; Takei, Y | 1 |
| Chowbay, B; Lye, KY; Moore, S; Olivo, M; Sharma, A; Zhou, Q | 1 |
| Baradari, V; Hopfner, M; Huether, A; Scherubl, H; Sutter, AP | 1 |
| Chao, TH; Cusack, JC; Liu, R; Neuteboom, ST; Niu, W; Palladino, MA; Palombella, VJ; Pien, C; Xia, L | 1 |
| Boschi, F; D'Onofrio, M; Faccioli, N; Marzola, P; Pozzi Mucelli, R; Sbarbati, A | 1 |
| Fujiwara, K; Hanai, M; Inoue, S; Ishida, S; Kimura, T; Kurakata, S; Senzaki, M; Yada, A | 1 |
| Anderson, WK | 1 |
| Hioki, K; Kameshita, I; Mohri, T; Suzuki, S; Takatani, S; Tokunaga, R | 1 |
| Ebisu, H; Fukuda, Y; Furuta, H; Oomori, Y; Seto, S; Terashima, S | 1 |
| Arencibia, JM; Groot, K; Halmos, G; Koppán, M; Nagy, A; Plonowski, A; Schally, AV | 1 |
| Amishiro, N; Gomi, K; Kobayashi, E; Nagamura, S; Saito, H | 1 |
| Cheng, CC; Zee-Cheng, KY | 1 |
7 review(s) available for pyrroles and Adenocarcinoma
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neovascularization, Pathologic; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib | 2013 |
Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Targeting angiogenesis in esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Disease-Free Survival; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Vascular endothelial growth factor in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Barrett Esophagus; Bevacizumab; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Indoles; Lymphangiogenesis; Neovascularization, Pathologic; Oxindoles; Prognosis; Propionates; Protein-Tyrosine Kinases; Pyrroles; RNA, Catalytic; RNA, Messenger; Vascular Endothelial Growth Factor A | 2004 |
Some antineoplastic antibiotics.
Topics: Adenocarcinoma; Amino Sugars; Animals; Antibiotics, Antineoplastic; Azaserine; Benzazepines; Bleomycin; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Cricetinae; Dactinomycin; Daunorubicin; DNA; Dogs; Glycosides; Haplorhini; Humans; Leukemia L1210; Liver Neoplasms; Lymphoma; Mice; Mitomycins; Naphthacenes; Plicamycin; Pyrroles; Rats; RNA; Sarcoma 180; Streptonigrin; Streptozocin | 1972 |
25 trial(s) available for pyrroles and Adenocarcinoma
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Combined Modality Therapy; Drug Interactions; Feasibility Studies; Goserelin; Humans; Indoles; Leuprolide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Radiotherapy, Intensity-Modulated; Seminal Vesicles; Sunitinib; Tosyl Compounds | 2013 |
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Female; Humans; Indoles; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrroles; Sunitinib; Survival Analysis | 2013 |
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Stomach Neoplasms; Sunitinib | 2013 |
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Pyrroles; Remission Induction; Salvage Therapy; Sunitinib; Survival Rate | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pyrroles; Stomach Neoplasms; Sunitinib | 2016 |
Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Castration; Disease-Free Survival; Humans; Indoles; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Quality of Life; Sunitinib | 2008 |
Phase II study of sunitinib in men with advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiogenic Proteins; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Radiography; Sunitinib; Taxoids; Time Factors; Treatment Outcome | 2009 |
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Pyrroles; Safety; Sunitinib; Survival Rate | 2010 |
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Esophagogastric Junction; Female; Humans; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2011 |
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pyrroles; Salvage Therapy; Sunitinib; Survival Rate; Treatment Outcome | 2010 |
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Castration; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2011 |
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Disease-Free Survival; Female; Humans; India; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Republic of Korea; Sunitinib; Survival Analysis; Thailand | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Indoles; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Pyrroles; Stomach Neoplasms; Sunitinib; Survival Rate; Tissue Distribution | 2013 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Anthracenes; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Gene Expression; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Oxindoles; Perylene; Photochemotherapy; Propionates; Protein-Tyrosine Kinases; Proteins; Pyrroles; Survival Rate | 2005 |
68 other study(ies) available for pyrroles and Adenocarcinoma
| Article | Year |
|---|---|
Palmar-plantar erythrodysesthesia syndrome resulting from toceranib phosphate in a dog with apocrine gland anal sac adenocarcinoma: a case report.
Topics: Adenocarcinoma; Anal Sacs; Animals; Apocrine Glands; Dog Diseases; Dogs; Male; Pyrroles | 2023 |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
Topics: Adenocarcinoma; Anal Gland Neoplasms; Anal Sacs; Animals; Apocrine Glands; Disease-Free Survival; Dog Diseases; Dogs; Female; Indoles; Male; Pyrroles; Retrospective Studies; Treatment Outcome; Wisconsin | 2020 |
Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
Topics: Adenocarcinoma; Animals; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dog Diseases; Dogs; Female; Indoles; Male; Neoplasm Recurrence, Local; Neoplasms; Pyrroles; Retrospective Studies; Treatment Outcome; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
Topics: Adenocarcinoma; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Autophagy; Benzamides; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Stomach Neoplasms | 2020 |
The Development of Foveolar-type Gastric Adenocarcinoma during Maintenance Therapy of Vonoprazan for Reflux Esophagitis.
Topics: Adenocarcinoma; Esophagitis, Peptic; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Recent Developments Pertaining to H. pylori Infection.
Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Pyrroles; Rifabutin; Stomach Neoplasms; Sulfonamides; Tetracycline; Treatment Outcome | 2021 |
Case 8-2021: A 34-Year-Old Woman with Cholangiocarcinoma.
Topics: Adenocarcinoma; Adult; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Fatal Outcome; Female; Hepatectomy; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pyrazoles; Pyrimidines; Pyrroles; Tomography, X-Ray Computed | 2021 |
Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Female; Indoles; Male; Pancreatic Neoplasms; Pyrroles; Retrospective Studies | 2021 |
A novel polyaniline/polypyrrole/graphene oxide fiber for the determination of volatile organic compounds in headspace gas of lung cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aniline Compounds; Cells, Cultured; Fibroblasts; Graphite; Humans; Lung Neoplasms; Polymers; Pyrroles; Solid Phase Microextraction; Volatile Organic Compounds | 2017 |
Autophagy Inhibition Enhances SPCA-1 Cell Proliferation Inhibition Induced by By-1 from the Stout Camphor Medicinal Mushroom, Taiwanofungus camphoratus (Agaricomycetes).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Agaricales; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Humans; Lung Neoplasms; Pyrroles | 2018 |
NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Mutation; Piperazines; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrroles | 2019 |
Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017).
Topics: Adenocarcinoma; Anal Sacs; Animals; Apocrine Glands; Dog Diseases; Dogs; Indoles; Pyrroles; Quality of Life; Retrospective Studies; Treatment Outcome | 2019 |
Suspected eccrine adenocarcinoma on footpad of the right hindlimb in a dog.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Biopsy; Dog Diseases; Dogs; Hindlimb; Immunohistochemistry; Indoles; Keratins; Male; Pyrroles; Sweat Gland Neoplasms; Vimentin | 2019 |
Glycosylation enhances the anti-migratory activities of isomalyngamide A analogs.
Topics: Adenocarcinoma; Amides; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glycosylation; Humans; Molecular Structure; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Renal Cell; Cisplatin; Cyclophosphamide; Diphosphonates; Doxorubicin; Female; Glutamates; Guanine; Humans; Imidazoles; Indoles; Interferons; Kidney Tubules; Lung Neoplasms; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Necrosis; Nephrectomy; Pemetrexed; Prednisone; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vincristine; Zoledronic Acid | 2013 |
Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Synergism; Humans; Lysosomes; Macrolides; Mice; Microtubule-Associated Proteins; Oxazepines; Pyrroles | 2013 |
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Indoles; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
Topics: Adenocarcinoma; Amyloid Precursor Protein Secretases; Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Colonic Neoplasms; Cyclic S-Oxides; Drug Synergism; Humans; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Organoplatinum Compounds; Oxaliplatin; Pyrroles; RNA, Small Interfering; Signal Transduction; Thiadiazoles | 2013 |
Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Autocrine Communication; Barrett Esophagus; Biomarkers; Biomarkers, Tumor; Cell Line; Cell Proliferation; Esophageal Neoplasms; Female; Humans; Immunohistochemistry; Indoles; MAP Kinase Signaling System; Mice; Phospholipase C gamma; Phosphorylation; Precancerous Conditions; Protein Kinase C; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Female; Indoles; Kidney; Liver; Mice, Inbred BALB C; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Angiogenesis Inhibitors; Animals; Blotting, Western; Cyclohexanes; Disease Models, Animal; Endostatins; Fibroblast Growth Factor 2; Finasteride; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Prostatic Neoplasms; Pyrroles; Sesquiterpenes; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Cell Proliferation; Colonic Neoplasms; Down-Regulation; Drug Synergism; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Pyrroles; Transcriptional Activation | 2015 |
Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Oncogene Proteins, Fusion; Pyrroles; Sunitinib | 2015 |
Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Benzoates; Benzoic Acid; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, EphA4; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.
Topics: Adenocarcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cohort Studies; DNA Replication; G1 Phase Cell Cycle Checkpoints; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Piperidones; Protein Serine-Threonine Kinases; Pyrroles; Transfection | 2016 |
P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Bevacizumab; Carcinogenesis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Indoles; Inhibitory Concentration 50; Male; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Prostatic Neoplasms; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
[Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclobutanes; Cytoskeletal Proteins; Heterografts; Humans; Lung Neoplasms; Lymph Nodes; Male; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Pyrroles; Random Allocation; RNA, Messenger; Sulfides; Transplantation, Heterologous; Tumor Burden | 2016 |
Mechanisms of SU5416, an inhibitor of vascular endothelial growth factor receptor, as a radiosensitizer for colon cancer cells.
Topics: Adenocarcinoma; Aging; Antineoplastic Agents; Apoptosis; beta-Galactosidase; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; DNA Repair; HCT116 Cells; HT29 Cells; Humans; Indoles; Neoplasm Invasiveness; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Reactive Oxygen Species; Receptors, Vascular Endothelial Growth Factor | 2016 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Sunitinib | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
Topics: Adenocarcinoma; Animals; Blotting, Western; Female; Fluorescent Antibody Technique; Gastrointestinal Neoplasms; Genes, Dominant; Humans; Immunoenzyme Techniques; Immunoprecipitation; Infusions, Subcutaneous; Matrix Metalloproteinase 7; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Somatomedins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma.
Topics: Acrospiroma; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Skin Neoplasms; Sunitinib; Treatment Outcome | 2010 |
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cisplatin; Humans; Lactones; Leupeptins; Male; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-raf; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Transfection; Tumor Cells, Cultured | 2009 |
Antimetastatic role of Smad4 signaling in colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Female; Humans; Liver Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Invasiveness; NM23 Nucleoside Diphosphate Kinases; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad4 Protein; Time Factors; Transfection; Transforming Growth Factor beta1; Urokinase-Type Plasminogen Activator | 2010 |
Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient.
Topics: Activities of Daily Living; Adenocarcinoma; Antineoplastic Agents; Carcinoembryonic Antigen; Colorectal Neoplasms; Compassionate Use Trials; Humans; Indoles; Male; Middle Aged; Pain; Pyrroles; Sunitinib | 2010 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Bisoprolol; Bone Neoplasms; Capecitabine; Colic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Heptanoic Acids; Humans; Hypercholesterolemia; Ileus; Leucovorin; Lymphatic Metastasis; Middle Aged; Nausea; Pyrroles; Ventricular Premature Complexes; Vomiting | 2011 |
Three cases of severe ulcerative esophagitis induced by SUTENT®.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Esophagitis; Gastrointestinal Hemorrhage; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Pyrroles; Sunitinib; Ulcer | 2012 |
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
Topics: Adenocarcinoma; Benzenesulfonates; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Selection, Genetic; Sorafenib; Sunitinib; Tongue Neoplasms | 2010 |
Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: novel antitumor DNA monoalkylating agents.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; DNA; Drug Screening Assays, Antitumor; Female; Humans; Melanoma; Pyrroles; Thiazoles | 2010 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; Male; Models, Biological; Oxazepines; Prostatic Neoplasms; Pyrroles; Tubulin Modulators | 2010 |
Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumor.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Nephrectomy; Pyrroles; Rare Diseases; Sunitinib | 2012 |
Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Azoxymethane; beta Catenin; Carcinogens; Colonic Neoplasms; Cyclin D1; eIF-2 Kinase; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunoenzyme Techniques; Interleukin-4; Male; Naproxen; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Inbred F344; Signal Transduction; Sulindac; Tumor Necrosis Factor-alpha | 2011 |
Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Flare up of symptoms after discontinuation of sunitinib in patient with lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Administration, Oral; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome; Withholding Treatment | 2011 |
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.
Topics: Adenocarcinoma; Adoptive Transfer; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Disease Models, Animal; Hep G2 Cells; Hepatocytes; Humans; Immune Tolerance; Immunocompetence; Indoles; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrroles; STAT3 Transcription Factor; Sunitinib | 2012 |
Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; NF-kappa B; Pravastatin; Pyrroles; Simvastatin | 2011 |
Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
Topics: Adenocarcinoma; Anal Gland Neoplasms; Anal Sacs; Animals; Antineoplastic Agents; Apocrine Glands; Bone Neoplasms; Carcinoma; Dog Diseases; Dogs; Female; Head and Neck Neoplasms; Indoles; Male; Neoplasms; Nose Neoplasms; Osteosarcoma; Pyrroles; Receptor Protein-Tyrosine Kinases; Skin Neoplasms; Thyroid Neoplasms | 2012 |
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Humans; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Pyrroles; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Anti-Idiotypic; Disease Models, Animal; Drug Therapy, Combination; Genetic Engineering; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.
Topics: Actinomycetales; Adenocarcinoma; Colonic Neoplasms; Crystallography, X-Ray; Cysteine Endopeptidases; Humans; Inhibitory Concentration 50; Lactones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrroles; Tumor Cells, Cultured | 2003 |
THE HUMAN TUMOR-EGG HOST SYSTEM. III. TUMOR-INHIBITORY PROPERTIES OF TENUAZONIE ACID.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspergillus; Azaserine; Carcinoma, Bronchogenic; Chick Embryo; Glycine; Mercaptopurine; Neoplasms; Neoplasms, Experimental; Puromycin; Pyrroles; Research; Saccharomyces; Tissue Culture Techniques; Triethylenemelamine | 1964 |
Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antineoplastic Agents; Base Pair Mismatch; Carrier Proteins; Cell Death; Colonic Neoplasms; Distamycins; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fibroblasts; Guanidines; Humans; Mice; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nitrogen Mustard Compounds; Nuclear Proteins; Proto-Oncogene Proteins; Pyrroles; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Movement; Cell Survival; Drug Synergism; Endostatins; Endothelium, Vascular; Female; Glioblastoma; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrroles; Ultrasonography; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2003 |
Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Metastasis; Ovarian Neoplasms; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Survival Analysis; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Cytotoxins; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; L-Lactate Dehydrogenase; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1 | 2006 |
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Colonic Neoplasms; Drug Administration Routes; Drug Synergism; Female; Humans; Lactones; Mice; Mice, Nude; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2006 |
Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.
Topics: Adenocarcinoma; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; Indoles; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Microcirculation; Neoplasms, Experimental; Organometallic Compounds; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Rats; Tamoxifen | 2007 |
CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Drug Screening Assays, Antitumor; Fluorouracil; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Pyrroles; Sulfonamides; Vascular Endothelial Growth Factor A | 2008 |
Off-label uses of sorafenib and sunitinib.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Digestive System Neoplasms; Drug Approval; Female; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Humans; Indoles; Male; Melanoma; Neoplasms, Squamous Cell; Product Labeling; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Small Cell; Cell Line; Colonic Neoplasms; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyrroles; Pyrrolidines; Transplantation, Heterologous | 1982 |
Rapid adhesion and spread of non-adherent colon cancer Colo201 cells induced by the protein kinase inhibitors, K252a and KT5720 and suppression of the adhesion by the immunosuppressants FK506 and cyclosporin A.
Topics: Adenocarcinoma; Carbazoles; Cell Adhesion; Cell Adhesion Molecules; Colonic Neoplasms; Cyclosporine; Cytoskeletal Proteins; Enzyme Inhibitors; Extracellular Matrix; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Immunosuppressive Agents; Indole Alkaloids; Indoles; Integrins; Neoplasm Metastasis; Paxillin; Phosphoproteins; Phosphorylation; Protein Kinase C; Protein-Tyrosine Kinases; Pyrroles; Sulfonamides; Tacrolimus; Tumor Cells, Cultured; Tyrosine | 1998 |
The novel cyclopropapyrroloindole(CPI) bisalkylators bearing 3,3'-(1,4-phenylene)diacryloyl group as a linker.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Benzylidene Compounds; Cell Division; Colonic Neoplasms; HeLa Cells; Humans; Mice; Pyrroles; Structure-Activity Relationship | 1998 |
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Doxorubicin; Drug Delivery Systems; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Models, Chemical; Polymerase Chain Reaction; Prostatic Neoplasms; Pyrroles; Receptors, LHRH; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
New water-soluble duocarmycin derivatives: synthesis and antitumor activity of A-ring pyrrole compounds bearing beta-heteroarylacryloyl groups.
Topics: Adenocarcinoma; Animals; Blood Platelets; Drug Screening Assays, Antitumor; HeLa Cells; Humans; In Vitro Techniques; Indoles; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Sarcoma 180; Stomach Neoplasms; Structure-Activity Relationship; Transplantation, Heterologous | 1999 |